Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Revenue (2016 - 2025)

Historic Revenue for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $6.0 million.

  • CytomX Therapeutics' Revenue fell 8216.38% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year decrease of 1025.61%. This contributed to the annual value of $138.1 million for FY2024, which is 3644.65% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Revenue stood at $6.0 million, which was down 8216.38% from $18.7 million recorded in Q2 2025.
  • CytomX Therapeutics' Revenue's 5-year high stood at $50.9 million during Q1 2025, with a 5-year trough of $6.0 million in Q3 2025.
  • In the last 5 years, CytomX Therapeutics' Revenue had a median value of $20.1 million in 2022 and averaged $21.3 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Revenue surged by 15994.47% in 2023, and later crashed by 8216.38% in 2025.
  • CytomX Therapeutics' Revenue (Quarter) stood at $11.1 million in 2021, then skyrocketed by 80.77% to $20.1 million in 2022, then soared by 32.22% to $26.6 million in 2023, then surged by 43.17% to $38.1 million in 2024, then plummeted by 84.35% to $6.0 million in 2025.
  • Its Revenue was $6.0 million in Q3 2025, compared to $18.7 million in Q2 2025 and $50.9 million in Q1 2025.